Journal ArticleDOI
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
About:
This article is published in Yearbook of Gastroenterology.The article was published on 2010-01-01. It has received 584 citations till now. The article focuses on the topics: Hepatitis C virus.read more
Citations
More filters
Journal ArticleDOI
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns,Samuel S. Lee,Joaquin Mario Valdes,Sabela Lens,Reem Ghalib,Humberto Aguilar,Franco Felizarta,Tarek Hassanein,Holger Hinrichsen,Diego Rincón,Rosa Maria Morillas,Stefan Zeuzem,Yves Horsmans,David R. Nelson,Yao Yu,Preethi Krishnan,Chih-Wei Lin,Jens Kort,Federico J. Mensa +18 more
TL;DR: The results show that 99% of patients treated with once-daily glecaprevir plus pibrentasvir achieved a sustained virological response at 12 weeks, and this drug regimen had a favourable safety profile in previously treated or untreated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis.
Journal ArticleDOI
Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More
TL;DR: Chronic HCV infection is curable with SVR attainment, and with cure comes improved liver histology and more favorable clinical outcomes, in comparison with patients who do not achieve the same therapeutic milestone.
Journal ArticleDOI
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
TL;DR: In this article, the authors developed a new pipeline for the development of hepatitis C drugs based on the telaprevir drug. But, the drug's development was once put on hold because of its performance in a standard IC(50) assay.
Journal ArticleDOI
HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV
Fasiha Kanwal,Fasiha Kanwal,Jennifer R. Kramer,Jennifer R. Kramer,Jawad A. Ilyas,Zhigang Duan,Hashem B. El-Serag,Hashem B. El-Serag +7 more
TL;DR: HCV genotype 3 is associated with a significantly increased risk of developing cirrhosis and HCC compared to HCV genotypes 1, independent of patients' age, diabetes, body mass index, or antiviral treatment.
Journal ArticleDOI
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
Paul J. Pockros,K. Rajender Reddy,Parvez S. Mantry,Eric Cohen,Michael J. Bennett,Mark S. Sulkowski,David E. Bernstein,Daniel E. Cohen,Nancy S. Shulman,Deli Wang,Amit Khatri,Manal Abunimeh,Thomas Podsadecki,Eric Lawitz +13 more
TL;DR: In a clinical trial, the combination of ombitasvir, paritaprevir, and ritonavir, administered with dasabuvir led to an SVR12 in 90% of patients with HCV genotype 1 infection and stage 4 or 5 CKD, though RBV use may require a reduction or interruption to manage anemia.
References
More filters
Journal ArticleDOI
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
TL;DR: Prevalence of hepatitis C cirrhosis and its complications will continue to increase through the next decade and will mostly affect those older than 60 years of age, but wider application of antiviral treatment and better responses with new agents could significantly reduce the impact of this disease in coming years.
Related Papers (5)
The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States
Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates.
Fernando Herz Wolff,Fernando Herz Wolff,Sandra Cristina Pereira Costa Fuchs,Sandra Cristina Pereira Costa Fuchs,Nêmora Tregnago Barcellos,Nêmora Tregnago Barcellos,Paulo Ricardo de Alencastro,Maria Letícia Rodrigues Ikeda,Ajácio Bandeira de Mello Brandão,Ajácio Bandeira de Mello Brandão,Maicon Falavigna,Flávio Danni Fuchs +11 more
Human immunodeficiency virus/hepatits C virus coinfection in Spain: elimination Is feasible, but the burden of residual cirrhosis will be significant
Juan Berenguer,Inmaculada Jarrín,Leire Pérez-Latorre,Víctor Hontañón,María J. Vivancos,Jordi Navarro,María Jesús Téllez,Josep M. Guardiola,José Antonio Iribarren,Antonio Rivero-Juárez,Manuel Márquez,Arturo Artero,Luis Morano,Ignacio Santos,J. Moreno,M.C. Fariñas,María José Galindo,María Nieves Aja Hernando,Marta Montero,Carmen Cifuentes,Pere Domingo,José Sanz,Lourdes Domíngez,Oscar Ferrero,Belén de la Fuente,Carmen Rodríguez,Sergio Reus,José Hernández-Quero,Gabriel Gaspar,Laura Pérez-Martínez,Coral García,Lluís Force,S. Veloso,Juan Emilio Losa,Josep Vilaró,Enrique Bernal,Sari Arponen,Amat Ortí,Ángel Chocarro,Ramón Teira,Gerardo Alonso,Rafael Silvariño,Ana Vegas,Paloma Geijo,Josep Bisbe,Herminia Esteban,Juan González-García +46 more